Xtant Medical Partners with Dilon Technologies for Exclusive Distribution of HEMOBLAST® Bellows in the U.S.
In a significant move within the medical technology sector, Xtant Medical Holdings, Inc. has entered into an exclusive distribution agreement with Dilon Technologies, Inc. for the advanced hemostatic product known as HEMOBLAST® Bellows. This partnership aims to enhance the availability of high-performance hemostatic solutions in the surgical market, addressing the needs of surgeons and patients alike.
Expanding Market Reach
The announcement came from Xtant Medical's President and CEO, Sean Browne, who expressed excitement about the collaboration. He emphasized that bringing HEMOBLAST to a broader audience of surgeons would significantly enhance their existing portfolio. With an estimated $2 billion global addressable market for hemostatic products, the collaboration enables both companies to penetrate this lucrative field more robustly. Xtant is not only acquiring the rights to distribute this product but has also integrated Dilon's U.S. sales team, which consists of about 20 seasoned professionals.
The Unique Attributes of HEMOBLAST®
Dilon Technologies CEO, George Makhoul, highlighted the differentiation of HEMOBLAST within the surgical hemostat market. The product features a unique formulation combining collagen with human-derived thrombin and bovine-derived chondroitin sulfate. This innovative composition enables HEMOBLAST Bellows to effectively manage minimal, mild, and moderate bleeding during various surgical procedures. Delivered through a user-friendly, pre-loaded applicator, HEMOBLAST streamlines the process for surgeons, as no preparation is required prior to its use.
Targeting Surgical Solutions
The HEMOBLAST is particularly valuable in situations where traditional methods of controlling bleeding are ineffective or impractical, especially outside of ophthalmic and urological procedures. Its versatility makes it a crucial tool in the surgical toolkit, enhancing patient safety and surgical efficiency by providing a reliable solution.
Looking to the Future
Xtant Medical's newly acquired distribution deal is expected to significantly influence its market performance, with plans to update its full-year 2026 financial guidance following the announcement. This venture aligns seamlessly with Xtant's mission to offer innovative surgical solutions that improve patient outcomes and elevate the standard of care in orthopedic procedures.
About the Companies
Xtant Medical focuses on developing strategic solutions that honor the gift of donation, enabling patients to live fulfilling lives. They specialize in orthopedic and chronic wound care innovations, and the addition of HEMOBLAST strengthens their commitment to providing comprehensive hemostatic solutions.
Conversely, Dilon Technologies, based in Newport News, Virginia, is dedicated to enhancing healthcare quality through innovative medical devices. Alongside HEMOBLAST Bellows, their portfolio includes advanced solutions such as MarginProbe and the trueView Pro 100, emphasizing their commitment to surgical excellence and patient care.
As the partnership unfolds, stakeholders from both companies and the broader medical community will be keenly observing how this agreement enhances surgical practices and ultimately impacts patient health outcomes.
Expanding Market Reach
The announcement came from Xtant Medical's President and CEO, Sean Browne, who expressed excitement about the collaboration. He emphasized that bringing HEMOBLAST to a broader audience of surgeons would significantly enhance their existing portfolio. With an estimated $2 billion global addressable market for hemostatic products, the collaboration enables both companies to penetrate this lucrative field more robustly. Xtant is not only acquiring the rights to distribute this product but has also integrated Dilon's U.S. sales team, which consists of about 20 seasoned professionals.
The Unique Attributes of HEMOBLAST®
Dilon Technologies CEO, George Makhoul, highlighted the differentiation of HEMOBLAST within the surgical hemostat market. The product features a unique formulation combining collagen with human-derived thrombin and bovine-derived chondroitin sulfate. This innovative composition enables HEMOBLAST Bellows to effectively manage minimal, mild, and moderate bleeding during various surgical procedures. Delivered through a user-friendly, pre-loaded applicator, HEMOBLAST streamlines the process for surgeons, as no preparation is required prior to its use.
Targeting Surgical Solutions
The HEMOBLAST is particularly valuable in situations where traditional methods of controlling bleeding are ineffective or impractical, especially outside of ophthalmic and urological procedures. Its versatility makes it a crucial tool in the surgical toolkit, enhancing patient safety and surgical efficiency by providing a reliable solution.
Looking to the Future
Xtant Medical's newly acquired distribution deal is expected to significantly influence its market performance, with plans to update its full-year 2026 financial guidance following the announcement. This venture aligns seamlessly with Xtant's mission to offer innovative surgical solutions that improve patient outcomes and elevate the standard of care in orthopedic procedures.
About the Companies
Xtant Medical focuses on developing strategic solutions that honor the gift of donation, enabling patients to live fulfilling lives. They specialize in orthopedic and chronic wound care innovations, and the addition of HEMOBLAST strengthens their commitment to providing comprehensive hemostatic solutions.
Conversely, Dilon Technologies, based in Newport News, Virginia, is dedicated to enhancing healthcare quality through innovative medical devices. Alongside HEMOBLAST Bellows, their portfolio includes advanced solutions such as MarginProbe and the trueView Pro 100, emphasizing their commitment to surgical excellence and patient care.
As the partnership unfolds, stakeholders from both companies and the broader medical community will be keenly observing how this agreement enhances surgical practices and ultimately impacts patient health outcomes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.